ONG41008

About ONG41008

  • ONG41008 is a new drug candidate which has therapeutic efficacy to both Idiopathic Pulmonary Fibrosis (IPF) and NonAlcoholic SteatoHepatitis (NASH).
  • It's a new molecule that can be protected by patents from around the world
  • It's on the path to finalize the Discovery phase and move to the Preclinical phase.

Idiopathic Pulmonary Fibrosis (IPF)

  • Idiopathic Pulmonary Fibrosis (IPF) is a progressive chronic interstitial lung disease with a high mortality rate. It is a rare disease with a high medical unmet need because there is no cure. (More Information : ONG21001 family )

NonAlcoholic SteatoHepatitis (NASH)

  • Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat is stored in your liver due to causes other than drinking.
  • NASH is a form of NAFLD that causes fibrosis due to liver inflammation and cell damage.
  • Between 30%~40% of adults in the United States have NAFLD and about 3%~12% of adults in the United States have NASH.
  • NASH can lead to complications, such as cirrhosis and liver cancer. If NASH leads to cirrhosis, and cirrhosis leads to liver failure that could leading to death.

Market information

  • There are no approved therapeutic.
  • The market was valued at US$ 0.7bn in 2016, and is expected to reach US$ 20bn by 2025, expanding at a CAGR of 46.1% from 2017 to 2025. (Source: Research and Markets)
  • Alarming rise in the diabetes and obesity prevalence would act as a driving factor for the growth of the market.

The Mechanism of ONG41008

  • The entire MOA is undefined. But one of the discovered roles of ONG41008 is an EMT inhibitor.

In vitro data

In vivo data – IPF

  • A comparative study of the efficacy of ONG41008 and Pirfenidon in a mouse model of pulmonary fibrosis induced by bleomycin.
  • ONG41008 showed better therapeutic efficacy than Pirfenidon, the best-selling IPF drug.

In vivo data – NASH

  • It's the results of therapeutic efficacy test using NASH-induced mouse model (STAM mouse).
  • ONG41008 reduced the area of ​​ballooning caused by excessive fat accumulation in the liver.
  • Overall, ONG41008 significantly reduced the NAFLD scores, demonstrated its potential as a new drug for NASH.